April 12th 2024
Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
FDA Gives Niraparib Fast Track Designation for Ovarian Cancer
September 19th 2016Niraparib has been granted a fast track designation by the FDA as a treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer, the company developing the PARP inhibitor, Tesaro, has announced.
Read More
Rucaparib Granted Priority Review for Ovarian Cancer
August 24th 2016Priority review has been granted by the FDA for a new drug application (NDA) for rucaparib as a treatment for patients with <em>BRCA</em>-positive advanced ovarian cancer who have received at least 2 prior lines of chemotherapy, according to Clovis, the manufacturer of the PARP inhibitor.
Read More
The Benefits and Risks of Bilateral Salpingo-Oophorectomy in the Treatment of Ovarian Cancer
August 10th 2016Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, discusses the benefits and risks of performing a bilateral salpingo-oophorectomy as a treatment for patients with ovarian cancer.
Watch
The Importance of Multi-Gene Panel Testing for BRCA Mutations
July 1st 2016Allison W. Kurian, MD, MSc, associate professor of Medicine and of Health Research and Policy, Stanford University School of Medicine, discusses two ongoing trials utilizing multi-gene panels to uncover previously undetected risks in patients with breast and ovarian cancer.
Watch
Novel Angiogenesis Inhibitor Shows Preliminary Evidence of Activity
June 10th 2016A novel dual-pathway inhibitor of tumor angiogenesis passed a preliminary clinical test, demonstrating manageable toxicity and biomarker evidence of engagement with the drug's targets, as reported at the 2016 ASCO Annual Meeting in Chicago.
Read More
Large Database Study Finds 11 Genes Associated with Increased Ovarian Cancer Risk
June 9th 2016The largest-ever genetic analysis of ovarian cancer patients yielded a short list of 11 suspect germline genetic mutations that may be associated with an increased risk for developing ovarian cancer, according to an oral presentation at the 2016 ASCO Annual Meeting in Chicago.
Read More
Niraparib/Bevacizumab Combo Meets Safety and Tolerability Objectives
June 9th 2016It is feasible to administer the PARP inhibitor niraparib in combination with bevacizumab to patients with platinum-sensitive relapsed ovarian cancer with manageable toxicities. The results of a phase I study (NCT02354131) in 12 patients were presented during a poster session at the 2016 ASCO Annual Meeting.
Read More
First-in-class "Stemness" Inhibitor Napabucasin Shows Promise in Advanced Ovarian Cancer
June 9th 2016Napabucasin (BBI-608, BB608) is a first-in-class cancer "stemness" inhibitor that targets the STAT3 pathway, has acceptable toxicity, and shows some antitumor activity in combination with paclitaxel in platinum-resistant ovarian cancer. Results of an early phase trial were presented at a poster session at the 2016 ASCO Annual Meeting.
Read More
Avelumab Shows Promise in Early Trial in Advanced Ovarian Cancer
June 9th 2016Avelumab (MSB0010718C), a fully human anti-PD-L1 (programmed death-1 receptor ligand) IgG1 antibody, showed activity in patients with heavily pretreated recurrent or refractory ovarian cancer with acceptable toxicity in the phase Ib JAVELIN Solid Tumor trial.
Read More
Olaparib Extends OS in Relapsed Ovarian Cancer
June 8th 2016The PARP inhibitor olaparib (Lynparza) significantly increased overall survival (OS) in women with platinum-sensitive relapsed serous ovarian cancer when given as maintenance monotherapy. These interim results, a third updated survival analysis, come from an extension of the Study 19 phase II trial and were presented at the 2016 ASCO Annual Meeting.
Read More
Durvalumab Combos Tested in Women's Cancers, and to be Tested in Basket Trial
June 8th 2016Durvalumab, an investigational PD-L1 targeting drug, is the subject of a unique ongoing basket trial being conducted by the National Institutes of Health, and was part of a single arm phase I combination therapy study of the drug in 19 patients with cervical cancer, triple negative breast cancer (TNBC), ovarian cancer, or uterine leiomyosarcoma.
Read More
Black Women Less Likely to Pursue BRCA Testing and Cancer Risk Reduction Measures
June 8th 2016Findings from a population-based study reported at the 2016 ASCO Annual Meeting revealed that young black women with breast cancer are much less likely to undergo testing for the BRCA gene or to get risk reducing prophylactic mastectomy or salpingo-oophorectomy than other women.
Read More
Novel TKI Examined in Metastatic Breast Cancer Patients with HER2 Mutation
June 8th 2016Neratinib, an experimental TKI being developed for breast cancer, achieved a 36% clinical benefit rate in a phase II trial, according to a poster presented June 5, 2016 at the ASCO Annual Meeting in Chicago.
Read More
IP Therapy Proves Non-Superior to IV/Bevacizumab Combination in Ovarian Cancer
April 26th 2016Intraperitoneal (IP) therapy was not superior to intravenous (IV) treatment when used in combination with bevacizumab (Avastin) as a regimen for patients with advanced ovarian cancer, according to phase III findings from the GOG-252 study.
Read More
Tumor Growth and Angiogenesis in Ovarian Cancer Linked to Key Adapter Protein
January 20th 2016Results from The Cancer Genome Atlas (TCGA) have shown that alterations in gene copy number (ie, amplifications or deletions) are an important characteristic of high-grade serous ovarian cancers (HGSOC).
Read More
Dr. Yael Cohen on VB111 as a Potential Treatment for Ovarian Cancer
December 28th 2015Yael Cohen, MD, discusses VB111, a highly targeted anti-angiogenic agent. The treatment is currently going through a phase III trial for treating glioblastoma, phase I trial for thyroid cancer and phase II trial for ovarian cancer.
Watch